LEXEO Therapeutics' LX2006 Receives the US FDA's Rare Pediatric Disease Designation and Orphan Drug Designation to Treat Friedreich Ataxia
Shots:
- The US FDA has granted RPD and ODD to LX2006 for the treatment of FA. The company plans to start a P-I/II clinical trial of LX2006 in patients with cardiomyopathy associated with FA in 2021
- Additionally- if BLA for LX2006 is approved- a company may be eligible to receive PRV that may be sold or transferred
- The company focuses to advance clinical programs to commercialization & maintain an ongoing research collaboration with Weill Cornell to foster the company’s pre-clinical pipeline. LX2006 (IV) is an AAV-mediated gene therapy encoding the human frataxin gene
| Ref: Globe Newswire | Image: Yahoo Finance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
